Recursion Pharmaceuticals, Inc. RXRX Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
As of June 30, 2026, assets pledged as collateral against finance leases totaled $13.8 million. Assets pledged as collateral are Lab Equipment reported in “Property and Equipment, net” on the Condensed Consolidated Balance Sheet. As of June 30, 2026, the liabilities associated with collateral pledged were solely comprised of a finance lease and had a carrying value of $13.9 million. The collateral pledged under the lease agreement may only be operated by the Company within the continental United States and must maintain a good title. The assets cannot be sold, disposed of or repledged by the Company.
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s finance lease liabilities?
- Recursion Pharmaceuticals, Inc. (RXRX) reported finance lease liabilities of $13.9M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s finance lease liabilities changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s finance lease liabilities decreased by 38.5% year-over-year, from $22.6M to $13.9M.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.
Ask your AI about Recursion Pharmaceuticals, Inc.'s finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
